Nicole Wakes, Senior Director Cell Line Development, and Simon Keen, Vice President Cell Line Development at Abzena, outline the strategies that developers must consider to overcome the challenges of developing BsAbs under increasing pressure for speed.
Advances in biotechnologies using molecules of complexity — such as bispecific antibodies (BsAbs) — offer broad applications in many disease areas, including asthma, macular degeneration, arthritis, and Crohn’s disease. When considering the production of these new-era biologics, a clear strategy is needed from the outset.